Alzheimer's disease treatments delisted in France
According the Prescrire, a French medical journal, drug treatments for Alzheimer's disease have been delisted in France and will no longer be reimbursed by the national health insurance system.
According to the article, the National Authority for Health (HAS) has previously issued guidance recommended treatments including donepezil, galantamine, rivastigmine and memantine. A review in 2016 of the harm-benefit balance of these treatments by France's Pharmacoeconomic Committee resulted in HAS acknowledging that these drugs have no place in the management of Alzheimer's disease.
Current guidance from NICE still recommends these treatments as options along with a range of other interventions to promote wellbeing and functional ability.
Action: Clinicians should continue to follow current NICE guidance however this move represents an interesting move away from medication in favour of supportive strategies for daily living that includes assistance for caregivers and family members.
| « CKS Updates - July 2018 | NICE Guidance - August 2018 » |
Just to record that my wife is on 2 x 1.5 Rivastigmine a day and we seriously wonder if the seeming side effects (tiredness & loss of balance) don't outweigh any of the (doubtful?) benefits.
No reply or comment necessary! Dick Tuckey
Comment by Antony Tuckey — March 20, 2019 #
[…] 2016年時，隸屬於法國HAS的藥物經濟學委員會於是作出評估，認為根據這類治療的「風險-利益比例」，也就是帶給病人的預期利益（治療效果）與潛在風險相較之下，不足以納入現有阿茲海默症的治療方案中；以2015年為例，阿茲海默症藥物讓法國健保支出將近9千萬歐元（相當於台幣31億5千萬左右）[2][3]。 […]
Pingback by 阿茲海默症藥物：希望或失望？ – 藥‧你小心！ — December 10, 2018 #